• Medscape InDiscussion: CAR T-Cell Therapy

  • By: Medscape
  • Podcast

Medscape InDiscussion: CAR T-Cell Therapy

By: Medscape
  • Summary

  • Listen to Medscape InDiscussion: CAR T-Cell Therapy, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987065). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
    Copyright 2023, Medscape
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • The Future of CAR T-cell Therapy
    Sep 12 2023

    Join Drs Amelia Langston and Frederick Locke as they discuss the future of CAR T-cell therapy research and treatment.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987070). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview

    Adoptive Cell Therapy https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adoptive-cell-therapy

    Graft Versus Host Disease (GVHD) https://emedicine.medscape.com/article/429037-overview

    Multiple Myeloma https://emedicine.medscape.com/article/204369-overview

    BCMA in Multiple Myeloma-A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/

    Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-shelf" T Cell Therapy Using iPSC Technology and Gene Editing https://pubmed.ncbi.nlm.nih.gov/35053386/

    Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview

    Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34466048/

    Preclinical and Clinical Studies of CAR-NK-cell Therapies for Malignancies https://pubmed.ncbi.nlm.nih.gov/36353643/

    How I Treat Cytopenias After CAR T-cell Therapy https://pubmed.ncbi.nlm.nih.gov/36800563/

    T-cell Receptor-based Therapy: An Innovative Therapeutic Approach for Solid Tumors https://pubmed.ncbi.nlm.nih.gov/34193217/

    Biochemistry, HLA Antigens https://www.ncbi.nlm.nih.gov/books/NBK546662/

    CAR T-cell Cancer Therapy Targeting Surface Cancer/Testis Antigens https://pubmed.ncbi.nlm.nih.gov/32983080/

    Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges https://pubmed.ncbi.nlm.nih.gov/36077696/

    Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/

    Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/

    Show more Show less
    19 mins
  • CAR T-Cell Therapy for Multiple Myeloma
    Aug 10 2023

    Join Drs Amelia Langston and Jonathan L. Kaufman, MD, as they discuss current CAR–T cell for B-cell lymphomas as leading researchers and practitioners in the field.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987069). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview

    Multiple Myeloma https://emedicine.medscape.com/article/204369-overview

    CD19 https://www.ncbi.nlm.nih.gov/gene/930

    BCMA in Multiple Myeloma - A Promising Key to Therapy https://pubmed.ncbi.nlm.nih.gov/34575199/

    Histology, Plasma Cells https://www.ncbi.nlm.nih.gov/books/NBK556082/

    Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/33626253/

    Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b/2 Open-Label Study https://pubmed.ncbi.nlm.nih.gov/34175021/

    Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? [Internet] https://www.ncbi.nlm.nih.gov/books/NBK137763/

    Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/36762851/

    Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies https://pubmed.ncbi.nlm.nih.gov/35877215/

    Bispecific Targeting of CD20 and CD19 Increases Polyfunctionality of Chimeric Antigen Receptor T-Cell Products in B-Cell Malignancies https://pubmed.ncbi.nlm.nih.gov/35597752/

    Bridging Chemotherapy: Multiple Myeloma https://www.ncbi.nlm.nih.gov/books/NBK584176/

    Autologous Bone Marrow Transplant https://www.cancer.gov/publications/dictionaries/cancer-terms/def/autologous-bone-marrow-transplant

    Myelodysplastic Syndrome (MDS) https://emedicine.medscape.com/article/207347-overview

    GPRC5D-Targeted CAR T Cells for Myeloma https://pubmed.ncbi.nlm.nih.gov/36170501/

    Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/36507686/

    Elotuzumab: The First Approved Monoclonal Antibody for Multiple Myeloma Treatment https://pubmed.ncbi.nlm.nih.gov/27493709/

    Natural Killer Cells in the Malignant Niche of Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/35087536/

    Show more Show less
    20 mins
  • CAR T-Cell Therapy for B-Cell Lymphomas
    Jul 11 2023

    Join Drs Amelia Langston and Loretta Nastoupil as they discuss current CAR T-cell therapy for B-cell lymphomas as leading researchers and practitioners in the field.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987068). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Axicabtagene Ciloleucel CAR T-cell Therapy in Refractory Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/29226797/

    Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/30501490/

    Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study https://pubmed.ncbi.nlm.nih.gov/32888407/

    Axicabtagene Ciloleucel as Second-line Therapy for Large B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34891224/

    Lisocabtagene Maraleucel Versus Standard of Care With Salvage Chemotherapy Followed by Autologous Stem Cell Transplantation as Second-line Treatment in Patients With Relapsed or Refractory Large B-cell Lymphoma (TRANSFORM): Results From an Interim Analysis of an Open-label, Randomised, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/35717989/

    Second-line Tisagenlecleucel or Standard Care in Aggressive B-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/34904798/

    KTE-X19 CAR T-cell Therapy in Relapsed or Refractory Mantle-cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/32242358/

    Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-arm, Multicentre, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/34895487/

    Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma (ZUMA-23) https://clinicaltrials.gov/ct2/show/NCT05605899

    Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122857/

    Show more Show less
    24 mins

What listeners say about Medscape InDiscussion: CAR T-Cell Therapy

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.